[go: up one dir, main page]

AR057401A1 - Derivados del 4,5- diarilpirrol , su preparacion y su aplicacion en terapeutica - Google Patents

Derivados del 4,5- diarilpirrol , su preparacion y su aplicacion en terapeutica

Info

Publication number
AR057401A1
AR057401A1 ARP060102708A ARP060102708A AR057401A1 AR 057401 A1 AR057401 A1 AR 057401A1 AR P060102708 A ARP060102708 A AR P060102708A AR P060102708 A ARP060102708 A AR P060102708A AR 057401 A1 AR057401 A1 AR 057401A1
Authority
AR
Argentina
Prior art keywords
alkyl
radical
substituted
group
independently selected
Prior art date
Application number
ARP060102708A
Other languages
English (en)
Inventor
Francis Barth
Laurent Hortala
Murielle Rinaldi-Carmona
Christian Congy
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR057401A1 publication Critical patent/AR057401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Reivindicacion 1: Compuesto de la formula (1) en la que: X representa un grupo -C(=O)-, SO2, -C(=O)N(R6)-; R1 representa un átomo de H o un grupo alquilo C1-4; R2 representa alquilo C1-12 no sustituido o sustituido una o varias veces con sustituyentes elegidos de manera independiente entre un átomo de halogeno, hidroxilo, alcoxi C1-4, alquiltio C1-4, fenoxi, radical trifluorometoxi, difluorometoxi, difluorometiltio o trifluorometiltio; un radical carbocíclico no aromático (C3-12) no sustituido o sustituido una o varias veces con sustituyentes elegidos de manera independiente entre alquilo C1-4, alcoxi C1-4, alquiltio C1-4, átomo de F, hidroxilo, radical trifluorometilo, difluorometilo, trifluorometoxi, difluorometoxi, trifluorometiltio o difluorometiltio; metilo sustituido con un radical carbocíclico no aromático (C3-12) no sustituido o sustituido una o varias veces con sustituyentes elegidos de manera independiente entre alquilo C1-4, alcoxi C1-4, alquiltio C1- 4, átomo de F, hidroxilo, radical trifluorometilo, difluorometilo, trifluorometoxi, difluorometoxi, trifluorometiltio o difluorometiltio; un radical fenilo, bencilo, bencidrilo o bencidrilmetilo, en el que cada grupo fenilo no está sustituido o está sustituido una o varias veces con sustituyentes elegidos de manera independiente entre un átomo de halogeno, hidroxilo, alquilo C1-4, alcoxi C1-4, metilendioxi, ciano, nitro, trifluorometilo, difluorometilo, difluorometoxi, trifluorometoxi, trifluorometiltio, difluorometiltio, grupo S(O)nAlk, OS(O)nAlk o alquilcarbonilo C1-4; un radical fenilo sustituido con un radical heterocíclico elegido entre pirrolilo, imidazolilo, piridilo o pirazolilo, no estando dicho radical heterocíclico sustituido o estando sustituido una o varias veces con uno o varios sustituyentes elegidos de manera independiente entre un átomo de halogeno o un grupo alquilo C1-4; un radical fenilo sustituido con un fenilo o fenoxi, en el que cada grupo fenilo no está sustituido o está sustituido una o varias veces con sustituyentes elegidos de manera independiente entre un átomo de halogeno, hidroxilo, alquilo C1-4, alcoxi C1-4, metilendioxi, ciano, nitro, trifluorometilo, difluorometilo, difluorometoxi, trifluorometoxi, trifluorometiltio, difluorometiltio, grupo S(O)nAlk, OS(O)nAlk o grupo alquilcarbonilo C1-4; 1,2,3,4-tetrahidronaftalen-2-ilo no sustituido o sustituido una o varias veces con alquilo C1-4 o trifluorometilo; un radical pirrolilo, imidazolilo, piridilo, pirazolilo, furilo, tienilo, oxazolilo o tiazolilo, no estando dichos radicales sustituidos o estando sustituidos con uno o varios sustituyentes elegidos de manera independiente entre un átomo de halogeno, un grupo alquilo C1- 4 o trifluorometilo, indol-2-ilo o N-metilindol-2-ilo; R3 representa alquilo C1-5 o cicloalquilo C3-7; R4 representa fenilo no sustituido o sustituido una o varias veces con sustituyentes elegidos de manera independiente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, ciano, radical difluorometilo, trifluorometilo, difluorometoxi, trifluorometoxi, grupo S(O)nAlk o OS(O)nAlk; R5 representa fenilo no sustituido o sustituido una o varias veces con sustituyentes elegidos de manera independiente entre un átomo de halogeno, alquilo C1-4, alcoxi C1-4, ciano, radical difluorometilo, trifluorometilo, difluorometoxi, trifluorometoxi, grupo S(O)nAlk o OS(O)nAlk; R6 representa un átomo de H o alquilo C1-4; n representa 0 1 o 2; Alk representa alquilo C1-4; en el estado de base o de sal de adicion de ácidos, así como en el estado de hidratos o de solvatos.
ARP060102708A 2005-06-27 2006-06-23 Derivados del 4,5- diarilpirrol , su preparacion y su aplicacion en terapeutica AR057401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0506609A FR2887548B1 (fr) 2005-06-27 2005-06-27 Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR057401A1 true AR057401A1 (es) 2007-12-05

Family

ID=35884019

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102708A AR057401A1 (es) 2005-06-27 2006-06-23 Derivados del 4,5- diarilpirrol , su preparacion y su aplicacion en terapeutica

Country Status (28)

Country Link
US (1) US7618995B2 (es)
EP (1) EP1899298B1 (es)
JP (1) JP5142152B2 (es)
KR (1) KR20080019641A (es)
CN (1) CN101208300A (es)
AR (1) AR057401A1 (es)
AT (1) ATE478045T1 (es)
AU (1) AU2006263781A1 (es)
BR (1) BRPI0612497A2 (es)
CA (1) CA2610805A1 (es)
CR (1) CR9565A (es)
DE (1) DE602006016285D1 (es)
DO (1) DOP2006000133A (es)
EA (1) EA200800149A1 (es)
EC (1) ECSP078009A (es)
FR (1) FR2887548B1 (es)
IL (1) IL188032A0 (es)
MA (1) MA29559B1 (es)
MX (1) MX2007016383A (es)
NO (1) NO20080458L (es)
NZ (1) NZ564195A (es)
PA (1) PA8681701A1 (es)
PE (1) PE20070169A1 (es)
SV (1) SV2007002580A (es)
TN (1) TNSN07439A1 (es)
TW (1) TW200740753A (es)
UY (1) UY29631A1 (es)
WO (1) WO2007000505A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874012B1 (fr) * 2004-08-09 2008-08-22 Sanofi Synthelabo Derives de pyrrole, leur preparation et leur utlisation en therapeutique
US20110118234A1 (en) * 2008-05-05 2011-05-19 Kaustav Biswas Urea Compounds as Gamma Secretase Modulators
FR2930939B1 (fr) * 2008-05-09 2010-07-30 Sanofi Aventis Derives de pyrrole, leur preparation et leur application en therapeutique
GB201103419D0 (es) 2011-02-28 2011-04-13 Univ Aberdeen
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
CH710832A1 (de) 2015-03-09 2016-09-15 Kaba Ag Programmierbarer Schliesszylinder.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335136A (en) * 1980-04-18 1982-06-15 E. I. Du Pont De Nemours And Company Anti-inflammatory 4,5-diaryl-α-(polyfluoroalkyl)-1H-pyrrole-2-methanamines
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5935990A (en) * 1996-12-10 1999-08-10 G.D. Searle & Co. Substituted pyrrolyl compounds for the treatment of inflammation
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
FR2874012B1 (fr) * 2004-08-09 2008-08-22 Sanofi Synthelabo Derives de pyrrole, leur preparation et leur utlisation en therapeutique

Also Published As

Publication number Publication date
EA200800149A1 (ru) 2008-04-28
MA29559B1 (fr) 2008-06-02
FR2887548B1 (fr) 2007-09-21
NO20080458L (no) 2008-01-24
DOP2006000133A (es) 2007-02-28
SV2007002580A (es) 2007-02-19
JP5142152B2 (ja) 2013-02-13
TW200740753A (en) 2007-11-01
DE602006016285D1 (de) 2010-09-30
UY29631A1 (es) 2007-01-31
AU2006263781A1 (en) 2007-01-04
IL188032A0 (en) 2008-03-20
PE20070169A1 (es) 2007-03-07
JP2008546829A (ja) 2008-12-25
US20080176924A1 (en) 2008-07-24
NZ564195A (en) 2010-01-29
US7618995B2 (en) 2009-11-17
CA2610805A1 (fr) 2007-01-04
TNSN07439A1 (en) 2009-03-17
EP1899298B1 (fr) 2010-08-18
ECSP078009A (es) 2008-01-23
EP1899298A2 (fr) 2008-03-19
WO2007000505A2 (fr) 2007-01-04
MX2007016383A (es) 2008-03-07
PA8681701A1 (es) 2007-01-17
FR2887548A1 (fr) 2006-12-29
ATE478045T1 (de) 2010-09-15
WO2007000505A3 (fr) 2007-11-15
BRPI0612497A2 (pt) 2010-11-23
CN101208300A (zh) 2008-06-25
CR9565A (es) 2008-04-10
KR20080019641A (ko) 2008-03-04

Similar Documents

Publication Publication Date Title
AR052673A1 (es) Derivados del 1,5-diarilpirrol,su preparacion y su aplicacion en la terapeutica
AR054799A1 (es) Derivados de oxindol
AR057705A1 (es) 3-acilaminobenzanilidas insecticidas
CO6160231A2 (es) Compuestos de isoindolina 5-substituidos
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
ECSP066695A (es) Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1
AR051288A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR055144A1 (es) Inhibidor de secrecion acida
AR044695A1 (es) Derivados de azolidina, utiles como herbicidas.
AR061370A1 (es) Derivados de imidazopirimidina
PE20110852A1 (es) Antagonistas del receptor de orexina de isonicotinamida
AR062125A1 (es) Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos
EP1900732A4 (en) NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
AR063518A1 (es) Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
AR063898A1 (es) Derivados de dihidro-h-pirazolo[4,3c]piridazin-3-ona sustituidos,metodo de preparacion,composiciones farmaceuticas que los contienen u usos en terapeutica para prevenir o tratar enfermedades en las que estan implicados receptores canabinoides cb1.
DK1755606T3 (da) Quinazolinonderivater, der er anvendelige som vanilloid-antagonister
DK1691607T3 (da) Anvendelse af N-arylhydrazinderivater til bekæmpelse af skadedyr
AR062679A1 (es) Derivados de eter diarilico y usos de los mismos
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
AR060800A1 (es) Derivados de aminometilpiridina su preparacion y su aplicacion en terapeutica
AR057401A1 (es) Derivados del 4,5- diarilpirrol , su preparacion y su aplicacion en terapeutica
AR052898A1 (es) Derivados de la n-[(4,5-difenil -2-tienil) metil] amina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para enfermedades mediadas por los receptores canabinoides cb1
PE20090961A1 (es) Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor

Legal Events

Date Code Title Description
FB Suspension of granting procedure